scholarly journals Uncommon Presentation of COVID-19 in Pediatric Patients: Anosmia

2021 ◽  
Vol 16 (02) ◽  
pp. 080-084
Author(s):  
Hatice Y. Dağlı ◽  
Özge M. Akcan ◽  
Sevgi Pekcan ◽  
Mustafa Gençeli ◽  
Hüseyin S. Özdemir ◽  
...  
Keyword(s):  
Pediatric Patients ◽  
Early Stage ◽  
Clinical Findings ◽  
World Health ◽  
The Novel ◽  
Uncommon Presentation ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Epidemiological Characteristics

Abstract Objective The novel coronavirus disease 2019 (COVID-19) infection was declared as a pandemic by the World Health Organization on March 11, 2020. Although the complaint of anosmia is well described in adult patients, there is limited knowledge in pediatric patients. We aim to evaluate the epidemiological characteristics and clinical findings of children with anosmia in COVID-19-positive pediatric patients. Methods Patients diagnosed with COVID-19 infection at 1 month to 18 years of age, who admitted to Meram Faculty of Medicine of Necmettin Erbakan University between March and June 2020, were retrospectively reviewed, and the patients who had anosmia or developed anosmia during follow-up were then included in the study. The diagnosis was established by polymerase chain reaction (PCR). Results A total of 71 patients were diagnosed with COVID-19 and 14 (19.7%) of them had anosmia. Mean patient age was 14.07 (range: 10–16) years. Six of our 14 (42.8%) patients had anosmia at the time of diagnosis and anosmia developed in the follow-up among eight patients. The mean duration of anosmia in our patients was 6.9 ± 3.8 days. Recovery time was 1 to 4 days in four patients (28.5%), 5 to 8 days in four patients (28.5%), and 9 to 14 days in six patients (42.8%). Conclusion In this article, it was emphasized that anosmia can be the sole manifestation or concomitant with other symptoms in children with COVID-19 disease. Care and attention is important to identify COVID-19 patients at an early stage of the disease and limit the spread of the virus.

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 862-869
Author(s):  
Meena Kumari ◽  
Monika Agrawal ◽  
Rakesh Kumar Singh ◽  
Parameswarappa S Byadgi
Keyword(s):  
World Health ◽  
Apical Surface ◽  
Therapy Assessment ◽  
Differentiated Cells ◽  
The World ◽  
Polarized Epithelia ◽  
Well Differentiated ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Epidemiological Characteristics

Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemiological characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and especially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19.

scholarly journals Potential of CRISPR/Cas13 System in Treatment and Diagnosis of COVID-19

2021 ◽  
Author(s):  
Amir Khodavirdipour ◽  
Motahareh Piri ◽  
Sarvin Jabbari ◽  
Mohammad Khalaj-kondori
Keyword(s):  
Diagnostic Tool ◽  
Human Kidney ◽  
World Health ◽  
Rapid Review ◽  
The Novel ◽  
Rapid Action ◽  
Antiparasitic Drug ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Treatment And Diagnosis

AbstractThe novel coronavirus disease 2019 (COVID-19) belongs to coronaviridae families, like sarbecovirus (SARS), and causes pyrexia, pertussis, and acute respiratory distress syndrome (ARDS) in major. Started from Wuhan, China now forced the World Health Organization (WHO) to call it a pandemic. These dreadful figures elevate the need for rapid action for a rapid diagnostic tool, an efficacious therapy, or vaccine for such widespread disease. Here we reviewed all the latest research and trials including conventional antiviral medicines that have a narrow and finite effect on COVID-19. Recently, some advances have been made by a nucleotide/nucleoside analogues (NUC) inhibitor (remdesivir), ivermectin (antiparasitic drug), and convalescent plasma, the later one has more recently been approved by the Food and Drug Administration (FDA). In addition, a clinical-grade soluble human angiotensin-converting enzyme (ACE2), named hrsACE2, was able to inhibit the infection of human blood vessel organoids, as well as the human kidney organoids, by the virus. As of now, innovative therapeutics based on the CRISPR/Cas13d might overcome the challenge of COVID-19 either as a treatment option or precise and rapid diagnostic tool due to its rapid and precise nature. In this updated comprehensive rapid review, we try to cover all recent findings in terms of genomics, diagnosis, prevention, and treatment.

scholarly journals Viability of Bacillus subtilis Cells in Airborne Bioaerosols on Face Masks

Atmosphere ◽  
2021 ◽  
Vol 12 (11) ◽  
pp. 1496
Author(s):  
Eun-Hee Lee ◽  
Yunsoo Chang ◽  
Seung-Woo Lee
Keyword(s):  
Bacillus Subtilis ◽  
World Health ◽  
The Novel ◽  
Fine Dust ◽  
Health Crisis ◽  
Viable Cells ◽  
Mask Material ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Sand Dust

The coronavirus disease 2019 (COVID-19) pandemic is a general health crisis and has irreversible impacts on human societies. Globally, all people are at risk of being exposed to the novel coronavirus through transmission of airborne bioaerosols. Public health actions, such as wearing a mask, are highly recommended to reduce the transmission of infectious diseases. The appropriate use of masks is necessary for effectively preventing the transmission of airborne bioaerosols. The World Health Organization (WHO) suggests washing fabric masks or throwing away disposable masks after they are used. However, people often use masks more than once without washing or disposing them. The prolonged use of a single mask might—as a result of the user habitually touching the mask—promote the spread of pathogens from airborne bioaerosols that have accumulated on the mask. Therefore, it is necessary to evaluate how long the living components of bioaerosols can be viable on the masks. Here, we evaluated the viability of airborne Bacillus subtilis (B. subtilis) in bioaerosols filtered on woven and anti-droplet (non-woven) face masks. As a simulation of being simultaneously exposed to sand dust and bioaerosols, the viability rates of bioaerosols that had accumulated on masks were also tested against fine dust and airborne droplets containing bacteria. The bioaerosols survived on the masks immediately after the masks were used to filter the bioaerosols, and the bacteria significantly proliferated after one day of storage. Thereafter, the number of viable cells in the filtered bioaerosols gradually decreased over time, and the viability of B. subtilis in bioaerosols on the masks varied, depending on the mask material used (woven or non-woven). Despite the reduction in viability, bioaerosols containing living components were still found in both woven and anti-droplet masks even after six days of storage and it took nine days not to have found them on masks. The number of viable cells in bioaerosols on masks significantly decreased upon exposure of the masks to fine dust. The results of this study should provide useful information on how to appropriately use masks to increase their duration of effectiveness against bioaerosols.

scholarly journals A Bittersweet Memoir

2021 ◽  
Vol 16 (1) ◽  
pp. 128-135
Author(s):  
Anita Y. N. Lim
Keyword(s):  
Video Clip ◽  
Early Period ◽  
General Medicine ◽  
University Hospital ◽  
World Health ◽  
Public Healthcare ◽  
The Novel ◽  
National University ◽  
Novel Coronavirus ◽  
Health Organization

Abstract I wrote this journal in March 2020 prior to the World Health Organization declaring the COVID-19 infection as a worldwide pandemic on March 11. The situation in Singapore was unfolding even as public healthcare institutions were tasked to lead the charge to contain the novel coronavirus as it was then called. This journal describes my experiences and impressions during my work in an isolation ward at the National University Hospital during this early period. I was to be catapulted into Pandemic Team 3 in the second and third weeks of February 2020. The urgency of hospital measures to respond to the novel coronavirus meant that the general medicine consultant roster which I was on was hijacked to support the pandemic wards. I thought wryly to myself that it was a stroke of genius to commandeer the ready-made roster of senior physicians; it would have been difficult for the roster monster to solicit senior physicians to volunteer when there were still so many unknowns about this virus. Graphic images of the dire situation in Wuhan, China, were circulating widely on social media. It was heart-wrenching to read of Dr. Li Wen Liang’s death. He had highlighted the mysterious pneumonia-causing virus. The video clip of him singing at a karaoke session that went viral underscored the tragedy of a young life cut short. Questions raced in my mind. “Are we helpless to prevent the spread of this virus?” “Is the situation in China to be replicated here in Singapore?” This seemed incredulous, yet, might it be possible? The immediate responses that jumped up within me was “yes, it’s possible, but let’s pray not. Whatever has to be done, must be done.”

scholarly journals Cutaneous presentation of COVID-19 Case Report

2020 ◽  
Vol 3 (3) ◽  
pp. 01-02
Author(s):  
Khadiga Ismail
Keyword(s):  
Public Health Emergency ◽  
World Health ◽  
The Novel ◽  
Scientific Journals ◽  
Global Public Health ◽  
The World ◽  
Global Spread ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Recent Attention

COVID-19 has high transmissibility and infectivity among human. On January 30, 2020, the World Health Organization (WHO) in an effort to slow down the global spread of the virus declared the outbreak, “A global public health emergency of international concern". The skin manifestations of the novel coronavirus COVID-19 were not recognized at the early stages of the pandemic but have received much recent attention in scientific journals. Reported manifestations range from pseudo-chilblains to a morbilliform (measles-like) exanthem, urticaria, vesicular eruptions, a dengue-like petechial rash and ovate scaling macules, and plaques mimicking pityriasis rosea.

scholarly journals Giant Cell Urothelial Carcinoma of Bladder

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Harshima Disvini Wijesinghe ◽  
Ajith Malalasekera
Keyword(s):  
Urothelial Carcinoma ◽  
Giant Cell ◽  
Early Stage ◽  
Giant Cells ◽  
World Health ◽  
World Health Organization Classification ◽  
Health Organization

Giant cell urothelial carcinoma is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumours. It is an aggressive tumour with a poor prognosis that usually presents at an advanced stage. It is characterized histologically by pleomorphic giant cells. We discuss a case of giant cell urothelial carcinoma presenting at an early stage in a previously well 62-year-old woman. Histology showed a tumour comprising pancytokeratin positive bizarre mononuclear and multi-nuclear giant cells admixed with areas of conventional urothelial carcinoma and carcinoma in situ. Three-month follow-up cystoscopy and magnetic resonance imaging showed no evidence of recurrence or pelvic lymphadenopathy.

A Qualitative Comparison of the Covex Respirator with Face Shield Versus the N95 Respirator

2020 ◽  
Author(s):  
Reid Mimmack ◽  
Elijah Germo ◽  
Garrett Augustine ◽  
Kumar Belani
Keyword(s):  
Filtration Efficiency ◽  
Current Medical ◽  
Pass Rate ◽  
World Health ◽  
Protective Equipment ◽  
The Novel ◽  
Qualitative Comparison ◽  
Medical Standard ◽  
Novel Coronavirus ◽  
Health Organization

Abstract In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) outbreak a worldwide pandemic. The pandemic led to concerns of shortages regarding healthcare-related resources, including personal protective equipment (PPE), ventilators, and more. The uniquely designed COVEX respirator with face shield was engineered and manufactured by Augustine Surgical, Inc. to combat the PPE shortage. The novel COVEX mask is an “all-in-one” face shield and filter with a Viral Filtration Efficiency (VFE) greater than 99%. A standard respirator qualitative fit test was completed on the COVEX respirator as well as the current medical standard 3M N95 respirator. Fit test studies comparing the two masks yielded similar outcomes. The COVEX respirator had a qualitative fit test pass rate of 96.6% and the 3M N95 respirator had a pass rate of 93.3% (n=30). Participants also reported other variables comparing the comfort and fit of each mask, which is described further in the discussion. The COVEX respirator with face shield passed a standardized qualitative fit test at a rate similar to the current medical standard N95 respirator. Our results suggest that the COVEX mask may be a viable PPE option in the future.

scholarly journals Emergency Radiology During the COVID-19 Pandemic: The Canadian Association of Radiologists Recommendations for Practice

2020 ◽  
Vol 71 (4) ◽  
pp. 425-430 ◽  
Author(s):  
Ciaran E. Redmond ◽  
Savvas Nicolaou ◽  
Ferco H. Berger ◽  
Adnan M. Sheikh ◽  
Michael N. Patlas
Keyword(s):  
Emergency Radiology ◽  
World Health ◽  
Guidance Document ◽  
Emergency Setting ◽  
The Novel ◽  
Canadian Association ◽  
Imaging Service ◽  
Emergency Imaging ◽  
Novel Coronavirus ◽  
Health Organization

Coronavirus Disease 2019 (COVID-19) is the disease caused by the novel coronavirus officially named the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), declared as a pandemic by the World Health Organization on March 11, 2020. The COVID-19 pandemic presents an unprecedented challenge to emergency radiology practice. The continuity of an effective emergency imaging service for both COVID-19 and non-COVID-19 patients is essential, while adhering to best infection control practices. Under the direction of the Board of the Canadian Association of Radiologists, this general guidance document has been synthesized by collaborative consensus of a group of emergency radiologists. These recommendations aim to assist radiologists involved in emergency diagnostic imaging to help mitigate the spread of COVID-19 and continue to add value to patient care in the emergency setting.

scholarly journals Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia

2019 ◽  
Vol 144 (7) ◽  
pp. 853-862
Author(s):  
Brett M. Lowenthal ◽  
Debashis Sahoo ◽  
Mahul B. Amin ◽  
Donna E. Hansel
Keyword(s):  
Median Time ◽  
De Novo ◽  
Clinical Findings ◽  
Malignant Potential ◽  
World Health ◽  
Time To Progression ◽  
Risk Of Progression ◽  
Health Organization ◽  
Subsequent Risk

Context.— Urothelial proliferation of unknown malignant potential (UPUMP) is a 2016 World Health Organization classifier that encompasses prior categories of flat and papillary urothelial hyperplasia. In addition, UPUMP occurs in settings of both de novo and prior bladder neoplasia. Objective.— To identify UPUMP features associated with subsequent neoplastic development. Design.— Sixty-eight patients were identified from the archives, including 26 patients with de novo and 42 patients with prior bladder neoplasia. Patient slides and clinical course were reviewed. Results.— Patients with de novo UPUMP were detected through clinical findings (26/26; 100%), whereas surveillance cystoscopy primarily detected UPUMP in patients with prior neoplasia (29/42; 69%). Histopathologic criteria evaluated included urothelial hyperplasia, urothelial cytology, vascular ingrowth, denudation, inflammation, edema, and fibrosis. Mean clinical follow-up was 68.9 months in patients with de novo neoplasia and 69.5 months in patients with prior neoplasia. Subsequent neoplasia developed in 4 of 26 (15.4%) of patients with de novo UPUMP and was associated with cystoscopic papillary appearance (P = .02) or microscopic thin papillary ingrowths or papillations (P = .02; median time to progression, 4.1 months). Of 42 patients with prior neoplasia, 17 (40.5%) had subsequent neoplasia, significantly associated with an absence of prominent lamina propria edema (P < .001; median time to progression, 11.0 months). A higher rate of progression to high-grade disease was present in patients with a prior neoplasia versus those with de novo disease (58.9% versus 25%). Conclusions.— Urothelial proliferation of unknown malignant potential shows subsequent risk of neoplastic development of 17% in patients with de novo disease and 40% in patients with prior neoplasia. The greatest risk of progression is associated with early papillary formation.

scholarly journals COVID-19: update of the Italian situation

2020 ◽  
Vol 26 (6) ◽  
pp. 834-837
Author(s):  
Carla Prezioso ◽  
Valeria Pietropaolo
Keyword(s):  
Local Level ◽  
National Level ◽  
World Health ◽  
The Novel ◽  
Northern Regions ◽  
Containment Measures ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Restrictive Measures ◽  
Italian Territory

AbstractOn the March 11, 2020, the World Health Organization (WHO) declared the novel coronavirus disease 2019 (COVID-19) outbreak as a pandemic. The first cases in Italy were reported on January 30, 2020, and quickly the number of cases escalated. On March 20, 2020, according to the Italian National Institute of Health (ISS) and National Institute of Statistics (ISTAT), the peak of COVID-19 cases reported in Italy reached the highest number, surpassing those in China. The Italian government endorsed progressively restrictive measures initially at the local level, and finally, at the national level with a lockdown of the entire Italian territory up to 3 May 2020. The complete Italian territory closing slowed down the contagion. This review retraces the main numbers of the pandemic in Italy. Although in decline, the new reported cases remain high in the northern regions. Since drugs or vaccines are still not available, the described framework highlights the importance of the containment measures to be able to quickly identify all the potential transmission hotspots and keep control subsequent epidemic waves of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document